ENDRA Life Sciences (NASDAQ:NDRA) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

ENDRA Life Sciences (NASDAQ:NDRA) issued its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), Zacks reports.

ENDRA Life Sciences Stock Performance

Shares of ENDRA Life Sciences stock traded down $0.01 during trading hours on Friday, reaching $0.04. The company’s stock had a trading volume of 24,017,083 shares, compared to its average volume of 9,370,943. ENDRA Life Sciences has a one year low of $0.04 and a one year high of $2.79. The company’s 50 day simple moving average is $0.09 and its 200 day simple moving average is $0.45. The stock has a market cap of $2.92 million, a P/E ratio of -0.03 and a beta of 0.82.

Shares of ENDRA Life Sciences are scheduled to reverse split before the market opens on Tuesday, August 20th. The 1-50 reverse split was announced on Friday, August 16th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 19th.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price objective on shares of ENDRA Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, June 7th.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.